Accumulating evidence has identified a mechanism potentially responsible for the inactivation of tumor suppressor genes, namely transcriptional silencing by aberrant methylation of CpG islands. A previous study has shown the loss of RUNX3 expression, due to aberrant methylation of its CpG island, in gastric cancer cell lines, suggesting that RUNX3 is a target for epigenetic gene silencing in gastric carcinogenesis. However, there are limited data on the methylation status of RUNX3 in the neoplastic and non-neoplastic tissues in various types of human cancers, including gastric cancer. Here, we report that 60% of gastric cancer cell lines and 64% of primary gastric carcinomas (n ¼ 75) were methylated at the RUNX3 CpG island. RUNX3 methylation was also detected in hepatocellular carcinomas (73%, n ¼ 48), larynx cancers (62%, n ¼ 37), lung cancers (46%, n ¼ 24), breast cancers (25%, n ¼ 25), prostate cancers (23%, n ¼ 44), endometrial cancers (12.5%, n ¼ 24), colon cancers (4.9%, n ¼ 61) and uterine cervical cancers (2.5%, n ¼ 40), showing that RUNX3 methylation is not restricted to gastric cancer. Interestingly, the RUNX3 methylation was especially frequent in tumors from tissues of a foregut derivative, that is, the stomach, liver, larynx and lung. Next, the methylation status of RUNX3 in various nonneoplastic tissues was examined, including the premalignant lesions of gastric carcinomas. The RUNX3 methylation was found in 8.1% of chronic gastritis (n ¼ 99), 28.1% of intestinal metaplasia (n ¼ 32), 27.3% of gastric adenomas (n ¼ 77) and 64% of gastric carcinomas (n ¼ 75), but not in chronic hepatitis B, normal prostate and colon mucosa, even though in cases of chronic hepatitis, the methylation frequency of its neoplastic tissues was very high. In conclusion, RUNX3 methylation is frequently found in human cancers, including gastric cancer, and is mostly cancer specific, with the exception of the stomach, and thus, might be useful as a potential diagnostic biomarker of cancer.
The mammalian RUNX protein is a transcription factor, containing a highly conserved DNA binding domain, designated as a 'runt domain' (RD), which shares a sequence similarity with Drosophila Runt. 1 Three different mammalian RUNX, termed RUNX1 (also called PEBP2aB/CBFA2/AML1), RUNX2 (PEBP2aA/CBFA1/AML3) and RUNX3 (PEBP2aC/ CBFA3/AML2), have been identified. All three RUNX proteins physically associate with SMAD proteins, downstream targets of the TGF-beta/BMP signaling, and play important roles in mammalian development.
2 RUNX1, especially, is required for hematopoiesis, 3 and its mutations have been observed in about 30% of human acute leukemia, 4 whereas RUNX2 is important for bone formation. 5 A recent study revealed that RUNX3 plays an important role in the genesis and progression of human gastric cancer, and functions as a tumor suppressor gene. 6 Aberrant methylation of promoter CpG islands, recognized as an alternative to gene mutation or deletion in human cancer, 7 is associated with transcriptional silencing of several genes, such as p16, 8 hMLH1, 9 RASSF1A 10 and E-cadherin, 11 in human cancer. Li et al. 6 showed the relationship of the loss of RUNX3 expression, in part, with aberrant methylation of its CpG island, in gastric cancer cell lines, suggesting that RUNX3 is a target for epigenetic gene silencing in gastric carcinogenesis. However, they did not examine the methylation status of RUNX3 in the premalignant stages of gastric carcinomas. If the aberrant methylation of RUNX3 contributes to tumor initiation, the methylation change would be expected to be found in the premalignant stages of gastric carcinomas. Another expectation is that the aberrant methylation of RUNX3 might be found in human cancers of other tissue types if RUNX3 serves as a tumor suppressor gene. At present, it is unknown whether RUNX3 methylation is restricted to gastric cancer or if it is a common event in human cancers of other tissue types.
In the present study, the methylation status of RUNX3 was studied in gastric carcinomas, their premalignant stages (chronic gastritis, intestinal metaplasia and gastric adenoma) and various types of human cancers. In addition, a topographic analysis of RUNX3 methylation was attempted in a stomach containing a gastric carcinoma.
Materials and methods

Tumor Samples and Cell Lines
Formalin-fixed, paraffin-embedded archival tissues of gastric carcinomas (n ¼ 74), gastric adenomas (n ¼ 77), chronic gastritis with/without intestinal metaplasia (n ¼ 32 and 99, respectively), hepatocellular carcinomas (n ¼ 48), lung cancers (n ¼ 24), larynx cancers (n ¼ 37), colon cancers (n ¼ 61), breast cancers (n ¼ 25), prostate cancers (n ¼ 44), endometrial cancers (n ¼ 24) and uterine cervical cancers (n ¼ 40) were obtained from the files of the Department of Pathology, Seoul National University Hospital, Seoul, Korea. Through light microscopic examination of the hematoxylin-eosin-stained slides, tissue blocks were selected for having tumor cells constituting more than 30% of their tumor volumes. Five gastric cancer cell lines (SNU-5, -484, -601, -620, and -719) were obtained from the Korean Cell Line Bank (Seoul), and were maintained in RPMI-1640 medium, supplemented with 10% fetal bovine serum and gentamycin (10 mg/ml), at 371C in a humidified 5% CO 2 atmosphere.
Topographic Analysis
Multiple tissue samples, from two surgically excised gastric cancers, were collected, snap-frozen and stored at À801C, until processed. The gastrectomy specimens were photographed and traced on a 2 cm grid, with the sites of biopsy marked to preserve the topographic relationship between biopsies. The samples were taken at 3 cm intervals along the longitudinal axis and 1.5 cm intervals along the vertical axis, from both the tumoral and nontumoral areas throughout the stomach.
DNA Preparation
The histologic sections, of 20 mm thickness, were dewaxed in xylene, with subsequent ethanol treatment. Genomic DNA was isolated by the standard method of proteinase K digestion and phenolchloroform/isoamylalcohol extraction.
Sodium Bisulfite Treatment and MSP
Both the normal and tumor DNAs were subjected to sodium bisulfite modification, as described previously. 12 Briefly, 5 mg of DNA was denatured with 2 M NaOH, followed by treatment with 1 mM hydroquinon and 3.5 M sodium sulfite, with incubation for 16 h at 551C. Following purification, using a JETSORB gel extraction kit (Genomed, Oeynhausen, Germany), the DNA was treated with 3 M NaOH, and precipitated with three volumes of 100% ethanol and a one-third volume of 7.5 M NH 4 Ac at À201C. The precipitated DNA was washed with 70% ethanol and dissolved in distilled water. The sodium bisulfite-modified DNA was subject to MSP using primer sets: methylated reactions, 
Bisulfite Genomic Sequencing
For bisulfite sequencing of five gastric cell lines, sodium bisulfite-treated genomic DNA was amplified using the following primers: 5 0 -ATT TTG GAG GAT TTG TTT TGG G-3 0 (sense) and 5 0 -CAA CCT ACC CRA CTA ATC CC-3 0 (antisense). The conditions of the amplification were as follows: 951C for 12 min, and 35 cycles of 951C for 30 s, 501C for 30 s, and 721C for 30 s, followed by final extension at 721C for 10 min. PCR reaction products were gelpurified and cloned into pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA). The inserted PCR fragments of individual clones were sequenced using an ABI Prism Dye Terminator Cycle Sequencing Kits (Perkin-Elmer, Foster City, CA, USA) and ABI Prism 377 DNA Sequencer (Perkin-Elmer).
Drug Treatment and RT-PCR
The cells were seeded at a density of 1 Â 10 6 cells/ 100 mm dish, and treated 24 h later with 5 mM of 5-aza-dC for 4 days. At the end of the treatment, the medium was removed and the RNA was isolated. cDNA was synthesized using M-MLV reverse transcriptase (Invitrogen), with random hexamers, following the manufacturer's instructions, and then amplified, with primers specific for the RUNX3 gene; 5 0 -GAG TTT CAC CCT GAC CAT CAC TGT G-3 0 (sense) and 5 0 -GCC CAT CAC TGG TCT TGA AGG TTG T-3 0 (antisense). The PCR reactions were performed as follows: 951C for 5 min, and 35 cycles of 951C for 30 s, 551C for 30 s and 721C for 30 s, followed by incubation at 721C for 10 min. b-actin was amplified to estimate the efficiency of cDNA synthesis as described previously. 13 The PCR products were resolved on 1% agarose gels.
Results
Methylation-specific PCR (MSP) was performed to analyze the methylation status of the RUNX3 CpG islands in gastric cancer cell lines. SNU-5 and SNU-484 cells were unmethylated at the RUNX3 CpG islands, whereas SNU-601, SNU-620 and SNU-719 cells were fully methylated at this locus (Figure 1a) . To verify MSP data and examine the density of methylated CpG sites, we performed bisulfite genomic sequencing on DNA from all cell lines. The promoter region spanning 30 CpG sites was amplified by PCR using sodium bisulfite-modified DNA as templates, and 3-5 PCR clones of each cell line were sequenced. As shown in Figure 1b , SNU-5 and SNU-484 cells were almost completely unmethylated at the CpG sites in the clones analyzed, whereas SNU-601, SNU-620 and SNU-719 cells showed the complete methylation pattern.
RUNX3 mRNA expression in these cell lines was evaluated by reverse-transcription PCR (RT-PCR). RUNX3 transcripts were observed in the unmethylated cell lines, but were not detected in any of the methylated cell lines (Figure 1c) . To determine whether DNA methylation might be involved in the loss of RUNX3 mRNA expression, three methylated cell lines (SNU-601, SNU-620 and SNU-719) were treated with the demethylating agent, 5-aza-2 0 deoxycytidine (5-aza-dC). Restoration of RUNX3 mRNA expression was observed in all the methylated cell lines after treatment with 5-aza-dC, confirming that the loss of RNUX3 mRNA expression was related to the aberrant methylation of its CpG islands ( Figure 1c) . Next, the RUNX3 methylation was examined to observe if it occurs in primary gastric cancer and various other types of human cancer. In all, 64% of primary gastric carcinomas (n ¼ 75) were found to be methylated at the RUNX3 CpG island, showing a frequency similar to those in a previous study 19 ( Figure 2 ). The RUNX3 methylation was also frequently detected in hepatocellular carcinomas (73%, n ¼ 48), larynx cancers (62%, n ¼ 37), lung cancers (46%, n ¼ 24), breast cancers (25%, n ¼ 25), prostate cancers (23%, n ¼ 44) and endometrial cancers (12.5%, n ¼ 24), but was rarely detected in colon cancers (4.9%, n ¼ 61) or uterine cervical cancers (2.5%, n ¼ 40). These results show that Accumulating evidence indicates that hypermethylation of CpG islands begins early in cancer progression, and in some cases, may precede the neoplastic process. If the aberrant methylation of certain genes contributes to tumor initiation, the methylation change would be expected to be found in premalignant lesions. To evaluate this possibility, the methylation status of RUNX3 in premalignant lesions of gastric carcinomas, including chronic gastritis, intestinal metaplasia and gastric adenomas, was examined. RUNX3 methylation was found in 8.1% of chronic gastritis (n ¼ 99), 28.1% of intestinal metaplasia (n ¼ 32), 27.3% of gastric adenomas (n ¼ 77) and 64% of gastric carcinomas (n ¼ 75). The difference in the methylation frequency was significant between chronic gastritis and intestinal metaplasia (P ¼ 0.006), and between intestinal metaplasia and gastric carcinomas (P ¼ 0.001). In addition, chronic liver disease (chronic hepatitis B) (n ¼ 40), normal prostate tissue (n ¼ 24) and normal colon tissue (n ¼ 60) were analyzed. However, RUNX3 methylation was not found in these tissues.
The spatial distribution of RUNX3 methylation was determined by MSP assays of multiple samples obtained from the topographic analysis of two cases of surgically resected gastric carcinoma (case 1, 53-year-old male; case 2, 42-year-old male). The results are depicted in Figure 3 , which clearly demonstrates that RUNX3 methylation was confined to the tumoral portion. One of 29 nontumoral samples harbored RUNX3 methylation in case 2, but none of the nontumoral samples showed RUNX3 methylation in case 1.
Discussion
Transcriptional silencing of tumor suppressor genes by aberrant methylation of CpG islands plays a crucial role in the development of various cancers. Many genes involved in the regulation of the cell cycle, tissue invasion, DNA repair and apoptosis have been shown to be inactivated by this type of epigenetic mechanism. Recently, the loss of RUNX3 expression, accompanied by the aberrant methylation of its promoter, was reported in gastric cancer cell lines. Consistent with these data, our results from MSP and RT-PCR showed the relation between the RUNX3 methylation status and its expression in gastric cancer cell lines.
In addition, whether RUNX3 methylation occurs in primary gastric cancer and various types of human cancers was examined. The results of this study show that RUNX3 methylation is not restricted to gastric cancer, but also occurs frequently in other types of cancer, such as liver, larynx, lung, breast, prostate and endometrial cancers, suggesting that the RUNX3 methylation constitutes a common feature of many cancers. However, it is necessary to confirm that RUNX3 methylation is representative of the loss of its expression in other types of cancer. RUNX3 genes can be transcribed from two alternative promoters, P1 (distal) and P2 (proximal), and therefore, expressed through a RUNX3 P1 promoter, even though P2 promoter was methylated. 14, 15 Contrary to the ubiquitously active P2 promoter, the activity of the P1 promoter is restricted to a few tissue types, such as the thymus and ovary, and there are no data for the activity of the P1 promoter in the various tissues examined. 15 It is important to note that loss of heterozygosity (LOH) at 1p36.1, where the RUNX3 gene locates, was detected in the most hypermethylated cases of testicular yolk sac tumors from infants. 16 Therefore, RUNX3 seems to follow the two-hit model of inactivation of tumor suppressor gene, namely loss of one allele and inactivation of the other by the hypermethylation. Further study on the LOH in various tumor tissues is also needed to better understand the molecular mechanism for the loss of RUNX3 expression. Products that were amplified with primers specific to the unmethylated or methylated alleles of RUNX3, following bisulfite modification, were loaded onto 2.5% agarose gels. L, 100-bp DNA ladder. (b) Frequency of RUNX3 methylation. RUNX3 methylation was frequently detected in gastric cancers (64%, n ¼ 75), hepatocellular carcinomas (73%, n ¼ 48), larynx cancers (62%, n ¼ 37), lung cancers (46%, n ¼ 24), breast cancers (25%, n ¼ 25), prostate cancers (23%, n ¼ 44) and endometrial cancers (12.5%, n ¼ 24), but was rarely detected in colon cancers (4.9%, n ¼ 61) or uterine cervical cancers (2.5%, n ¼ 40).
In recent years, several attempts have been made to examine the methylation status of specific genes in the premalignant stages of cancer. 17, 18 In this study, it was found that RUNX3 methylation occurs in chronic gastritis, the early stages of multistep gastric carcinogenesis, although the methylation frequency (8.1%) was lower than those of intestinal metaplasia (28.1%) or gastric adenomas (27.3%). The methylation frequency of RUNX3 was much higher in gastric carcinomas (64%) than those in premalignant lesions. This result suggests that RUNX3 methylation increases with the progression of the lesion along the multistep gastric carcinogenesis, and is related to the genesis of gastric carcinomas. Recently, Waki et al 19 reported that 8% of non-neoplastic gastric mucosa, from patients without gastric cancer, harbored the RUNX3 methylation, which were seen only in patients aged over 77 years. In the present study, RUNX3 methylation was found in non-neoplastic gastric mucosa, from patients without gastric cancer, aged younger than 50 years (3.2%, two of 62), and with methylation frequencies of 17.9, 20 and 13.6% in patients in their 6th, 7th and 8th decades, respectively, exhibiting an increase in the methylation with aging. In contrast to the non-neoplastic gastric mucosa, RUNX3 methylation was not found in other nonneoplastic tissues, such as chronic hepatitis B, prostate and colon mucosa, even though in hepatitis, the methylation frequency of its neoplastic tissues was very high. Taken together, with the exception of the stomach, RUNX3 methylation was very rare in non-neoplastic tissues, so the methylation can be regarded as a cancer-specific change. In the stomach, RUNX3 methylation is cancer-related, but can also occur in non-neoplastic gastric mucosa.
When the methylation frequency of RUNX3 was compared between different tissue types of human cancers, an interesting trend was observed; high frequencies of RUNX3 methylation were seen in tumors from tissues of a foregut derivative, that is, the stomach, liver, larynx and lung. In Esteller et al's study, 20 which investigated the methylation pattern of human cancers of multiple tissue types, the methylation patterns of gastric cancer were similar to those of colon cancer. However, the RUNX3 methylation showed the contrast between gastric cancer and colon cancer.
In conclusion, RUNX3 methylation was frequently found in human cancers, including gastric cancer, and was mostly cancer specific, with the exception of the stomach, and thus might be useful as a potential diagnostic biomarker of cancer. Cancer Epigenetics, and by the BK21 project for Medicine, Dentistry, and Pharmacy, Seoul, Korea.
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